Skip to main content

Vernal Keratoconjunctivitis

3
Pipeline Programs
4
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
1
1
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Sandoz
SandozAustria - Kundl
1 program
1
Cyclosporine APhase 41 trial
Active Trials
NCT01211327Completed366Est. Nov 2008
Biocorp
BiocorpFrance - Issoire
2 programs
1
1
Cyclosporine A 0,05% eye dropPhase 31 trial
Lactobacillus Rhamnosus GGPhase 2/31 trial
Active Trials
NCT00445120Completed48Est. Jan 2009
NCT00426023Completed48Est. Oct 2008
Santen
SantenCA - Emeryville
1 program
NOVA22007 ''Ciclosporin''PHASE_31 trial
Active Trials
NCT01751126Completed169Est. Feb 2016
Novartis
NovartisBASEL, Switzerland
1 program
Cyclosporine APHASE_4

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
SandozCyclosporine A
SantenNOVA22007 ''Ciclosporin''
BiocorpCyclosporine A 0,05% eye drop
BiocorpLactobacillus Rhamnosus GG

Clinical Trials (4)

Total enrollment: 631 patients across 4 trials

NCT01211327SandozCyclosporine A

Topical Cyclosporine for Vernal Keratoconjunctivitis (VKC) in Rwanda

Start: Jul 2008Est. completion: Nov 2008366 patients
Phase 4Completed
NCT01751126SantenNOVA22007 ''Ciclosporin''

Double-Masked Trial of NOVA22007 (1mg/mL Ciclosporin/Cyclosporine) Versus Vehicle in Pediatric Patients With Active Severe Vernal Keratoconjunctivitis

Start: Apr 2013Est. completion: Feb 2016169 patients
Phase 3Completed
NCT00426023BiocorpCyclosporine A 0,05% eye drop

Cyclosporin A Eye Drop Treatment in Vernal Keratoconjunctivitis

Start: Feb 2007Est. completion: Oct 200848 patients
Phase 3Completed
NCT00445120BiocorpLactobacillus Rhamnosus GG

Lactobacillus Rhamnosus GG Oral Treatment Efficacy on Vernal Keratoconjunctivitis Treatment

Start: Mar 2007Est. completion: Jan 200948 patients
Phase 2/3Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.